This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Conte, J. E.
Right arrow Articles by Zurlinden, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Conte, J. E., Jr.
Right arrow Articles by Zurlinden, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2002, p. 1475-1480, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1475-1480.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Intrapulmonary Pharmacokinetics of Linezolid

John E. Conte, Jr.,1,2* Jeffrey A. Golden,2 Juliana Kipps,1 and Elisabeth Zurlinden1

Infectious Diseases Research Group, Department of Epidemiology & Biostatistics,1 Department of Medicine, University of California, San Francisco, San Francisco, California 94143-09192

Received 18 May 2001/ Returned for modification 23 November 2001/ Accepted 2 February 2002

In this study, our objective was to determine the steady-state intrapulmonary concentrations and pharmacokinetic parameters of orally administered linezolid in healthy volunteers. Linezolid (600 mg every 12 h for a total of five doses) was administered orally to 25 healthy adult male subjects. Each subgroup contained five subjects, who underwent bronchoscopy and bronchoalveolar lavage (BAL) 4, 8, 12, 24, or 48 h after administration of the last dose. Blood was obtained for drug assay prior to administration of the first dose and fifth dose and at the completion of bronchoscopy and BAL. Standardized bronchoscopy was performed without systemic sedation. The volume of epithelial lining fluid (ELF) recovered was calculated by the urea dilution method, and the total number of alveolar cells (AC) was counted in a hemocytometer after cytocentrifugation. Linezolid was measured in plasma by a high-pressure liquid chromatography (HPLC) technique and in BAL specimens and AC by a combined HPLC-mass spectrometry technique. Areas under the concentration-time curves (AUCs) for linezolid in plasma, ELF, and AC were derived by noncompartmental analysis. Half-lives for linezolid in plasma, ELF, and AC were calculated from the elimination rate constants derived from a monoexponential fit of the means of the observed concentrations at each time point. Concentrations (means ± standard deviations) in plasma, ELF, and AC, respectively, were 7.3 ± 4.9, 64.3 ± 33.1, and 2.2 ± 0.6 µg/ml at the 4-h BAL time point and 7.6 ± 1.7, 24.3 ± 13.3, and 1.4 ± 1.3 µg/ml at the 12-h BAL time point. Linezolid concentrations in plasma, ELF, and AC declined monoexponentially, with half-lives of 6.9, 7.0, and 5.7 h, respectively. For a MIC of 4, the 12-h plasma AUC/MIC and maximum concentration/MIC ratios were 34.6 and 3.9, respectively, and the percentage of time the drug remained above the MIC for the 12-h dosing interval was 100%; the corresponding ratios in ELF were 120 and 16.1, respectively, and the percentage of time the drug remained above the MIC was 100%. The long plasma and intrapulmonary linezolid half-lives and the percentage of time spent above the MIC of 100% of the dosing interval provide a pharmacokinetic rationale for drug administration every 12 h and indicate that linezolid is likely to be an effective agent for the treatment of pulmonary infections.

* Corresponding author. Mailing address: University of California, San Francisco, 350 Parnassus Ave., Suite 507, San Francisco, CA 94117. Phone: (415) 476-1312. Fax: (415) 476-0760. E-mail: jconte{at}aids.ucsf.edu.

Antimicrobial Agents and Chemotherapy, May 2002, p. 1475-1480, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1475-1480.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Yew, W. W., Chang, K. C., Chau, C. H. (2009). Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 64: 1119-1119 [Full Text]  
  • Dietze, R., Hadad, D. J., McGee, B., Molino, L. P. D., Maciel, E. L. N., Peloquin, C. A., Johnson, D. F., Debanne, S. M., Eisenach, K., Boom, W. H., Palaci, M., Johnson, J. L. (2008). Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med. 178: 1180-1185 [Abstract] [Full Text]  
  • Gupta, R., Wargo, K. A. (2008). An Update on the Management of Nosocomial Pneumonia. Journal of Pharmacy Practice 21: 380-389 [Abstract]  
  • Kiem, S., Schentag, J. J. (2008). Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid. Antimicrob. Agents Chemother. 52: 24-36 [Full Text]  
  • Gotfried, M. H., Shaw, J.-P., Benton, B. M., Krause, K. M., Goldberg, M. R., Kitt, M. M., Barriere, S. L. (2008). Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other Antibiotics. Antimicrob. Agents Chemother. 52: 92-97 [Abstract] [Full Text]  
  • de Jesus Valle, M. J., Uranga, N. S., Lopez, F. G., Hurle, A. D.-G., Navarro, A. S. (2007). Disposition of linezolid in the isolated rat lung after systemic and pulmonary drug delivery. J Antimicrob Chemother 60: 1074-1079 [Abstract] [Full Text]  
  • Salerno, D., Vahid, B., Marik, P. E. (2007). Methicillin-Resistant Staphylococcus Aureus Pneumonia After Thoracic Surgery: Successful Treatment With Linezolid After Failed Vancomycin Therapy. Ann. Thorac. Surg. 83: 1888-1891 [Abstract] [Full Text]  
  • Maclayton, D. O, Hall II, R. G (2007). Pharmacologic Treatment Options for Nosocomial Pneumonia Involving Methicillin-Resistant Staphylococcus aureus. The Annals of Pharmacotherapy 41: 235-244 [Abstract] [Full Text]  
  • Myrianthefs, P., Markantonis, S. L., Vlachos, K., Anagnostaki, M., Boutzouka, E., Panidis, D., Baltopoulos, G. (2006). Serum and Cerebrospinal Fluid Concentrations of Linezolid in Neurosurgical Patients. Antimicrob. Agents Chemother. 50: 3971-3976 [Abstract] [Full Text]  
  • Buerger, C., Plock, N., Dehghanyar, P., Joukhadar, C., Kloft, C. (2006). Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.. Antimicrob. Agents Chemother. 50: 2455-2463 [Abstract] [Full Text]  
  • Kollef, M. H., Micek, S. T. (2005). Staphylococcus Aureus Pneumonia: A "Superbug" Infection in Community and Hospital Settings. Chest 128: 1093-1097 [Full Text]  
  • Panidis, D., Markantonis, S. L., Boutzouka, E., Karatzas, S., Baltopoulos, G. (2005). Penetration of Gentamicin Into the Alveolar Lining Fluid of Critically Ill Patients With Ventilator-Associated Pneumonia. Chest 128: 545-552 [Abstract] [Full Text]  
  • Guna, R., Munoz, C., Dominguez, V., Garcia-Garcia, A., Galvez, J., de Julian-Ortiz, J.-V., Borras, R. (2005). In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother 55: 950-953 [Abstract] [Full Text]  
  • Schriever, C., Zeitz-Colaizzi, L., Quinn, A., Schriever, A. E., Cannon, J. P. (2005). Considerations for the Management of Gram-Positive Pathogens in the Intensive Care Unit. Journal of Pharmacy Practice 18: 100-108 [Abstract]  
  • (2005). Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am. J. Respir. Crit. Care Med. 171: 388-416 [Full Text]  
  • Voils, S. A., Kim, K. S., Wittbrodt, E. T. (2005). Recent Trends in the Management of Ventilator-Associated Pneumonia. Journal of Pharmacy Practice 18: 53-62 [Abstract]  
  • Conte, J. E. Jr., Golden, J. A., Kipps, J., McIver, M., Zurlinden, E. (2004). Intrapulmonary Pharmacokinetics and Pharmacodynamics of Itraconazole and 14-Hydroxyitraconazole at Steady State. Antimicrob. Agents Chemother. 48: 3823-3827 [Abstract] [Full Text]  
  • Combes, A., Luyt, C.-E., Fagon, J.-Y., Wollf, M., Trouillet, J.-L., Gibert, C., Chastre, J. (2004). Impact of Methicillin Resistance on Outcome of Staphylococcus aureus Ventilator-associated Pneumonia. Am. J. Respir. Crit. Care Med. 170: 786-792 [Abstract] [Full Text]  
  • Conte, J. E. Jr., Golden, J. A., Kipps, J., Zurlinden, E. (2004). Steady-State Plasma and Intrapulmonary Pharmacokinetics and Pharmacodynamics of Cethromycin. Antimicrob. Agents Chemother. 48: 3508-3515 [Abstract] [Full Text]  
  • Bosso, J. A., Flume, P. A., Gray, S. L. (2004). Linezolid Pharmacokinetics in Adult Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 48: 281-284 [Abstract] [Full Text]  
  • Fish, D. N. (2003). Bronchoscopic Sampling of Drug Concentrations: Penetration to Tissue Is the Issue. Am. J. Respir. Crit. Care Med. 168: 1263-1265 [Full Text]  
  • Wunderink, R. G., Rello, J., Cammarata, S. K., Croos-Dabrera, R. V., Kollef, M. H. (2003). Linezolid vs Vancomycin: Analysis of Two Double-Blind Studies of Patients With Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia. Chest 124: 1789-1797 [Abstract] [Full Text]  
  • Honeybourne, D., Tobin, C., Jevons, G., Andrews, J., Wise, R. (2003). Intrapulmonary penetration of linezolid. J Antimicrob Chemother 51: 1431-1434 [Abstract] [Full Text]  
  • Humphrey, W. R., Shattuck, M. H., Zielinski, R. J., Kuo, M.-S. T., Biermacher, J. J., Smith, D. P., Jensen, J. L., Schaadt, R. D., Zurenko, G. E., Richards, I. M. (2003). Pharmacokinetics and Efficacy of Linezolid in a Gerbil Model of Streptococcus pneumoniae-Induced Acute Otitis Media. Antimicrob. Agents Chemother. 47: 1355-1363 [Abstract] [Full Text]  
  • Danesi, R., Lupetti, A., Barbara, C., Ghelardi, E., Chella, A., Malizia, T., Senesi, S., Angeletti, C. A., Del Tacca, M., Campa, M. (2003). Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. J Antimicrob Chemother 51: 939-945 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»